

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

47-17745-01

Docket or Reference number

030-13268

Amendment No. 14

St. Francis Hospital
333 Laidley Street
P. O. Box 471
Charleston, West Virginia 25322

In accordance with application (letter) dated July 2, 1985, License No. 47-17745-01 is amended as follows:

Items 1 and 2 the licensee's name and address are changed.

FROM: St. Francis Hospital
519 Donnally Street
Charleston, West Virginia 25301

TO: St. Francis Hospital
333 Laidley Street
P. O. Box 471
Charleston, West Virginia 25322

Conditions 10, 12 and 17 are amended to read as follows:

10. Licensed material shall be used only at the licensee's facilities at 333 Laidley Street, Charleston, West Virginia.
12. A. Licensed material listed in Item 5 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:
- | | |
|-------------------------|--|
| W. Alva Deardorff, M.D. | Groups I through V |
| Paul Francke, M.D. | Groups I through V |
| Thomas M. Hayes, M.D. | Groups I, II and III
Iodine 131 for treatment of
hyperthyroidism, cardiac
dysfunction, and thyroid carcinoma
Phosphorus 32 as colloidal chromic
phosphate for intracavitary
treatment of malignant effusions |
| Martin S. Wershba, M.D. | Groups I, II and III
Iodine 131 for treatment of
hyperthyroidism, cardiac
dysfunction, and thyroid carcinoma |
| Carl R. Duncan, M.D. | Groups I, II and III |

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

47-17745-01

Docket or Reference number

030-13268

Amendment No. 14

(con't)

CONDITIONS

Ravindra K. Goginenia, M.D.

Groups I, II and III
Iodine 131 as iodine for thyroid uptake studies, and for treatment of hyperthyroidism and cardiac dysfunction

Alan R. Nichols, M.D.

Groups I, II and III

Carl B. Binns, M.D.

Groups I, II and III
Phosphorus 32 as colloidal
Chromic phosphate for intracavitary treatment of malignant effusions

D. Abramowitz, M.D.

Groups I, II and III
Iodine 131 as iodide for treatment of hyperthyroidism and thyroid carcinoma

B. The Radiation Protection Officer for the activities authorized by this license is Carl R. Duncan, M.D.

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in letters dated September 16, 1977, November 23, 1977, December 5, 1977, January 12, 1978, April 10, 1980, March 22, 1982, June 25, 1982, and January 17, 1983; application dated January 18, 1983, and letters dated April 5, 1983, July 28, 1983, August 17, 1983, and September 22, 1983; application dated June 5, 1984 and letters dated July 16, 1984 and July 2, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

EARL G. WRIGHT

Date JUL 30 1985

By

Earl G. Wright
Region II, Nuclear Materials
Safety Section101 Marietta Street, Suite 2900
Atlanta, GA 30323